International Flavors & Fragrances Inc. research snapshot
IFF AI stock analysis currently reads International Flavors & Fragrances as a defensive specialty ingredients, taste, scent, and biosciences company with improving operating execution but still meaningful balance sheet and portfolio-transition risk. The stock closed at $81.83 on July 7, 2026, with a mechanically verified market capitalization near $20.89 billion using 255.3 million shares. The AI view is cautiously constructive: upside depends on volume growth, productivity, Food Ingredients sale execution, debt reduction, and margin recovery, while downside risk rises if customer demand weakens, raw material costs pressure Scent, free cash flow stays thin, or divestiture timing slips. This page is for informational research only and is not investment advice.
Current price
$81.83
Market cap
$20.89 billion
AI score
63 / 100
Rating
Defensive specialty ingredients franchise, margin recovery and leverage watch
Trend status
Positive multi-week rebound, close to 52-week high
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | IFF sells flavors, fragrances, food ingredients, cultures, enzymes, probiotics, and bioscience solutions used in everyday consumer and industrial products. | High |
| Moat | The moat comes from formulation know-how, regulatory and safety trust, customer co-development, sensory libraries, manufacturing scale, and switching friction in validated product recipes. | Medium-high |
| Management | Erik Fyrwald is pushing portfolio simplification, productivity, R&D focus, and debt reduction, with the Food Ingredients sale as the key capital allocation test. | Medium-high |
| Financial trend | FY2025 net sales were $10.89 billion, adjusted operating EBITDA was $2.086 billion, and free cash flow was $256 million. Q1 2026 sales were $2.741 billion with $568 million adjusted operating EBITDA. | High |
| Valuation | At $81.83, verified math shows about 19.5x FY2025 adjusted EPS ex amortization, 1.48x book value, 1.92x sales, and a 1.96% dividend yield. GAAP P/E is not meaningful because FY2025 EPS was negative. | Medium |
| Technical trend | IFF rallied strongly over the last month and closed only 3.10% below its $84.45 52-week high, but it had two consecutive down days into July 7. | Medium |
| Risk level | Risk is elevated by leverage, goodwill and intangible exposure, raw material and currency swings, customer destocking cycles, Food Ingredients sale execution, and thin reported free cash flow. | Medium-high |
| AI confidence | Descriptive research confidence is high because public filings and company releases are rich. Forward return confidence is lower because the thesis depends on execution and portfolio timing. | High data confidence |
| Investment certainty | IFF has a more durable product role than its recent GAAP losses imply, but the stock needs real deleveraging and cash-flow proof before certainty improves. | Medium-low |
IFF AI stock forecast
The IFF AI stock forecast is scenario-based, not a precise price promise. Using the July 7, 2026 close of $81.83, FY2025 adjusted EPS ex amortization of $4.20, and a three-year valuation model, the tested outputs were about $46.80 in a bear case, $82.60 in a base case, and $116.40 in a bull case before dividends.
$105 to $120
More likely if comparable currency-neutral sales grow in the 1% to 4% guidance range, adjusted operating EBITDA reaches or exceeds the $2.05 billion to $2.15 billion guidance range, Food Ingredients proceeds reduce debt, and free cash flow conversion improves materially.
$78 to $86
More likely if IFF delivers modest EPS growth, holds margins after portfolio actions, keeps net debt near management targets, and the market values the company near a high-teens adjusted earnings multiple.
$44 to $50
More likely if volume recovery fades, raw material costs pressure Scent, Food Ingredients sale benefits are delayed, leverage remains high, or investors reprice IFF as a slow-growth and capital-intensive specialty chemical company.
IFF AI technical analysis
IFF AI technical analysis is constructive but extended as of the July 8, 2026 data cutoff. MarketWatch reported that IFF closed at $81.83 on July 7, 2026, after a 1.14% decline and a second straight down day. IFF was still only 3.10% below the $84.45 52-week high reached on February 17, and company IR trading statistics showed a 14.01% four-week gain as of July 6. Because this static page does not fetch request-time chart data, moving averages and intraday levels should be confirmed in a live chart before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $81.83 | MarketWatch reported the July 7, 2026 close at $81.83. |
| Near support | $80 to $81 | This zone centers on the recent breakout area and the July 1 close near $81.15. Holding it keeps the rebound intact. |
| Deeper support | $76 to $78 | This range gives room for a normal pullback after the five-day winning streak that ended on July 6. |
| Near resistance | $84 to $85 | This zone covers the reported $84.45 52-week high and the nearest upside test. |
| Breakout confirmation | Close above $85 | A close above the prior high with strong volume would improve the trend-following setup. |
| 50-day moving average | Requires live chart confirmation | Use current chart data before acting. The page does not fetch request-time market data. |
| 200-day moving average | Requires live chart confirmation | Long-term trend confirmation should be checked against a live chart or broker data. |
| Momentum | Positive but cooling | Company IR showed a 14.01% four-week gain as of July 6, but MarketWatch reported two consecutive down days into July 7. |
| Volume | 1.8 million shares | MarketWatch reported July 7 volume below the 50-day average of about 2.0 million shares. |
| Invalidation | Close below $76 | A decisive close below deeper support would weaken the recovery setup and shift focus back to leverage and cash-flow risk. |
IFF AI trading strategy
The IFF AI trading strategy below is a rules-based research framework, not personal investment advice. It connects portfolio simplification, margin recovery, debt reduction, and live chart confirmation with predefined invalidation levels.
Watch for IFF to hold $80 to $81 and then close above $85 with volume that confirms demand. Pair the chart with evidence that Q2 2026 results still support the 2026 sales and adjusted EBITDA guidance ranges.
A failed breakout near $84 to $85 or a close below $76 should invalidate the short-term setup.
If IFF pulls back toward $76 to $78 without a thesis break, review free cash flow, net debt to credit-adjusted EBITDA, raw material costs, Food Ingredients sale status, and customer volume trends before treating the decline as opportunity.
Do not average down without a predefined maximum loss, because leverage and portfolio execution can turn a valuation reset into a balance-sheet problem.
Track comparable currency-neutral sales, adjusted operating EBITDA margin, cash flow from operations, free cash flow, Food Ingredients sale milestones, debt paydown, dividend coverage, and demand in Taste, Scent, and Health & Biosciences.
Reduce confidence when the stock rises mainly on sale-process headlines without matching cash-flow conversion and debt reduction evidence.
Investment research summary
IFF is paid because consumer brands need trusted taste, scent, texture, health, bioscience, and formulation inputs that make products repeatable, differentiated, safe, and acceptable to regulators and end customers.
IFF benefits from sensory science, formulation libraries, customer co-development, regulatory approvals, global manufacturing, and switching costs embedded in validated recipes. The moat is stronger in high-touch innovation projects than in commodity-like food ingredients.
The thesis fails if IFF cannot turn volume growth into free cash flow, if raw material or currency pressure absorbs productivity gains, if goodwill and intangible assets require more charges, or if the Food Ingredients sale leaves stranded costs and weaker scale.
Management is simplifying the portfolio, selling Food Ingredients, reinvesting in R&D, and prioritizing debt reduction. The key test is whether capital allocation improves cash returns rather than only reducing reported complexity.
Taste, scent, health, and biosciences sit inside durable consumer demand for flavor, fragrance, wellness, clean-label, and functional ingredients. Growth is steadier than explosive, and competition from Givaudan, Firmenich, Symrise, Kerry, and in-house customer teams keeps pricing power contested.
At about 19.5x adjusted EPS ex amortization and 1.92x sales, IFF is priced for a recovery, not distress. Margin of safety depends on debt reduction, better free cash flow, and proof that the post-divestiture company can grow with higher margins.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IFF price | $81.83 at July 7, 2026 close | MarketWatch | July 8, 2026 |
| Market capitalization | $20.89 billion, verified as $81.83 x 255.30 million shares | financial_rigor.py market cap verification | July 8, 2026 |
| Shares outstanding | 255.30 million shares outstanding; average FY share count 256.00 million | IFF IR trading statistics via LSEG | July 8, 2026 |
| Management ownership | 2026 proxy reported all directors and executive officers as a group held 2,736,456 shares; a May 2026 Form 4 summary reported CEO Erik Fyrwald directly held 109,676 shares after RSU tax withholding | IFF 2026 proxy and Form 4 summary | July 8, 2026 |
| FY2025 revenue | $10.89 billion, cross-validated with IFF, Macrotrends, and StockTitan | IFF FY2025 results | July 8, 2026 |
| FY2025 GAAP earnings | Net loss attributable to IFF shareholders of $374 million and reported EPS of $(1.46), affected by goodwill impairment and portfolio charges | IFF FY2025 results | July 8, 2026 |
| FY2025 adjusted EBITDA and free cash flow | $2.086 billion adjusted operating EBITDA and $256 million free cash flow | IFF FY2025 results | July 8, 2026 |
| Q1 2026 revenue and earnings | $2.741 billion sales, $169 million net income attributable to IFF shareholders, $568 million adjusted operating EBITDA, and $0.66 reported EPS | IFF Q1 2026 results | July 8, 2026 |
| Q1 2026 cash and debt | $562 million cash and cash equivalents; about $5.994 billion short-term borrowings plus long-term debt by company balance-sheet line items | IFF Q1 2026 results | July 8, 2026 |
| 2026 guidance | $10.5 billion to $10.8 billion sales and $2.05 billion to $2.15 billion adjusted operating EBITDA | IFF Q1 2026 results | July 8, 2026 |
| Food Ingredients sale | Transaction values the business at about $4.3 billion; IFF expects about $3.8 billion net cash proceeds and plans to prioritize debt reduction | IFF Food Ingredients sale announcement | July 8, 2026 |
| Valuation check | 19.48x adjusted EPS ex amortization, 1.48x book value, 81.83x FY2025 free cash flow per share, 1.92x sales, and 1.96% dividend yield | financial_rigor.py valuation verification | July 8, 2026 |
| 52-week high, trend, and volume | $84.45 52-week high on February 17, 2026; 14.01% four-week gain as of July 6; 1.8 million shares traded on July 7 | IFF IR trading statistics and MarketWatch | July 8, 2026 |
This IFF AI stock analysis page is an informational research tool. It is not investment advice, a recommendation, or a guarantee of future returns. Forecast ranges are scenarios based on available public data as of the cutoff date and can be wrong.
